Pharmaceutical compositions having a pharmaceutically acceptable copper antagonist compound(s) or a pharmaceutically acceptable salt or prodrug thereof, including copper (II) antagonists, and a pharmaceutically acceptable 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor or a pharmaceutically acceptable salt or prodrug thereof, articles and kits and delivery devices containing such compositions, tablets and capsules and formulations containing such compositions, and methods of use for treatment of subjects, including humans, who have or are at risk for various diseases, disorders, and conditions.